Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT1306 plus XELOX in EBV-associated gastric cancer
CTR20181775Phase 2Terminated
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bat1306 in gastric cancer (GC), esophagogastric junction cancer, sponsored by Bio-Thera Solutions, Ltd.. Started Jan 2019; status: terminated.
02
Drugs
bat1306
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on CTR20181775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181775.